Ozempic works by mimicking a natural gut hormone called GLP-1 that your body already produces after eating. The drug’s active ingredient, semaglutide, is 94% structurally identical to human GLP-1, but it’s engineered to last much longer in your system. While your body’s natural GLP-1 breaks down within minutes, semaglutide has a half-life of about seven days, which is why it only needs to be injected once a week.
The medication activates GLP-1 receptors in three key areas: your pancreas, your digestive tract, and your brain. Each of these does something different, and together they lower blood sugar and reduce body weight.
What Happens in Your Pancreas
When you eat and your blood sugar rises, Ozempic signals your pancreas to release more insulin. This is called glucose-dependent insulin secretion, and the “glucose-dependent” part matters: the drug only triggers extra insulin when blood sugar is actually elevated, which lowers the risk of dangerous blood sugar drops compared to some older diabetes medications. At the same time, semaglutide reduces the release of glucagon, a hormone that tells your liver to dump more sugar into your bloodstream. Less glucagon means less sugar entering your blood between meals.
Semaglutide also promotes the growth of beta cells, which are the insulin-producing cells in your pancreas. In people with type 2 diabetes, beta cells are often damaged or depleted, so this effect helps the pancreas work more effectively over time.
How It Slows Your Digestion
Ozempic slows the rate at which food leaves your stomach and enters your small intestine. This is called delayed gastric emptying, and it has two practical effects. First, nutrients get absorbed more gradually, which prevents the sharp blood sugar spikes that typically follow a meal. Second, food sitting in your stomach longer makes you physically feel full for an extended period after eating.
A study in 72 adults with obesity found that semaglutide at the 2.4 mg dose measurably slowed stomach emptying over a 20-week period. This slower digestion is also one reason many people experience nausea when starting the medication, since the stomach isn’t clearing as quickly as the brain expects.
What Changes in Your Brain
The appetite effects of Ozempic go well beyond just keeping food in your stomach longer. Semaglutide crosses into the brain and activates GLP-1 receptors in several regions that control hunger, fullness, and food reward.
The hypothalamus is the primary target. Within it, semaglutide activates neurons in an area called the dorsomedial hypothalamus, which controls what researchers call “cognitive satiation,” essentially the mental sense that you’ve had enough to eat. When these neurons fire, they send inhibitory signals to other neurons that normally drive hunger and food-seeking behavior. In animal studies, activating these neurons triggered immediate meal termination, while blocking them caused animals to eat more and for longer.
Semaglutide also stimulates neurons that produce feelings of fullness while simultaneously quieting neurons that generate hunger signals and cravings. The net result is that many people on Ozempic describe a fundamental shift in their relationship with food: they think about it less, feel satisfied with smaller portions, and find it easier to pass on foods they previously couldn’t resist.
Beyond the hypothalamus, GLP-1 receptors exist in the brain’s reward pathways and in brainstem areas that process gut signals. Neurons in one brainstem region produce satiety without discomfort, while neurons in a neighboring area are more associated with nausea. This helps explain why the medication can reduce appetite through two distinct channels, one pleasant (genuine satisfaction with less food) and one less so (queasiness).
How Much Weight People Actually Lose
In a real-world study published in JAMA Network Open, patients lost an average of 5.9% of their body weight at three months and 10.9% at six months. At the six-month mark, 87% of patients had lost at least 5% of their weight, about 55% had lost 10% or more, and roughly 24% had lost 15% or more. Individual results varied widely, ranging from less than 1% to over 29% weight loss at six months.
Higher doses produced greater weight loss. Patients on 1.7 or 2.4 mg lost an average of 12.1% of their body weight by six months, compared to 9.2% for those on lower doses. People with type 2 diabetes tended to lose less weight than those without, averaging 7.2% at six months compared to 11.8% for people without diabetes.
Blood Sugar Improvements
For people with type 2 diabetes, Ozempic lowers HbA1c (a measure of average blood sugar over three months) significantly. Across the SUSTAIN clinical trials, the 1 mg dose reduced HbA1c by 0.38 to 1.07 percentage points more than comparison treatments. To put that in context, a 1-point drop in HbA1c is considered clinically meaningful and is associated with a substantially lower risk of diabetes complications.
How Dosing Works
Ozempic is injected once weekly under the skin, typically in the abdomen, thigh, or upper arm. You start at 0.25 mg for the first four weeks, which is not a treatment dose. It’s designed to let your body adjust and minimize side effects. After four weeks, the dose increases to 0.5 mg, which is the first maintenance dose. If blood sugar control isn’t sufficient after at least another four weeks, your dose can increase to 1 mg, and eventually to a maximum of 2 mg.
Because of its seven-day half-life, semaglutide takes four to five weeks to reach steady levels in your body at any given dose. This is why the gradual dose escalation matters: each increase needs several weeks to fully take effect.
Common Side Effects
Gastrointestinal issues are by far the most frequent side effects, and they tie directly to how the drug works. Slowed stomach emptying and altered gut signaling cause nausea in about 44% of people on the higher dose, compared to 16% on placebo. Diarrhea affects roughly 30%, vomiting about 25%, and constipation about 24%.
These side effects are most common during dose escalation and tend to decrease over time as the body adjusts. The gradual titration schedule exists specifically to reduce the severity of these symptoms. For most people, nausea is mild to moderate and doesn’t lead to stopping the medication, though a minority do find it intolerable enough to discontinue.